Literature DB >> 16445823

Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation.

Kumi Aita1, Shinichi Ito, Kazunari Tanabe, Hiroshi Toma, Yutaka Yamaguchi, Michio Nagata.   

Abstract

Dense deposit disease (DDD), also known as type II membranoproliferative glomerulonephritis (MPGN), is characterized by the presence of continuous intramembranous dense deposits. At present, the histogenesis of DDD is not well known. Reported herein are two cases of early recurrence of DDD in renal allografts, with marked endocapillary proliferation. In case 1 the first allograft biopsy revealed electron-dense deposits mainly in the subendothelial and mesangial areas along with subepithelial humps, but a continuous intramembranous deposition was not obvious. In the sequential biopsy, the deposits were more often seen in the intramembranous area and finally formed a continuous osmiophilic substance, which is a characteristic feature of DDD. In case 2, continuous intramembranous deposition already coexisted with endocapillary proliferation at the first biopsy. In both cases, endocapillary proliferation was alleviated slightly as time progressed. The present report suggests that endocapillary proliferative glomerulonephritis is the earliest lesion in some cases of DDD. Detailed review of a clinical history and a subsequent follow-up biopsy should be done to distinguish these lesions from other types of endocapillary proliferative glomerulonephritis.

Entities:  

Mesh:

Year:  2006        PMID: 16445823     DOI: 10.1111/j.1440-1827.2006.01931.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Dense deposit disease and the factor H H402 allele.

Authors:  Keith K Lau; Richard J Smith; Peter C Kolbeck; Lavjay Butani
Journal:  Clin Exp Nephrol       Date:  2008-01-26       Impact factor: 2.801

Review 2.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.